Investigating the Association Between Polygenic Risk Scores for Alzheimer's Disease With Cognitive Performance and Intrinsic Functional Connectivity in Healthy Adults.
Alzheimer’s disease (AD)
cognition
genetic disposition
intrinsic functional connectivity
polygenic risk score (PRS)
resting-state fMRI
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
08
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
Alzheimer's disease (AD) pathology is present many years before the onset of clinical symptoms. AD dementia cannot be treated. Timely and early detection of people at risk of developing AD is key for primary and secondary prevention. Moreover, understanding the underlying pathology that is present in the earliest stages of AD, and the genetic predisposition to that might contribute to the development of targeted disease-modifying treatments. In this study, we aimed to explore whether genetic disposition to AD in asymptomatic individuals is associated with altered intrinsic functional connectivity as well as cognitive performance on neuropsychological tests. We examined 136 cognitively healthy adults (old group: mean age = 69.32, SD = 4.23; young group: mean age = 31.34, SD = 13.12). All participants had undergone resting-state functional magnetic resonance imagining (fMRI), DNA genotyping to ascertain polygenic risk scores (PRS), and neuropsychological testing for global cognition, working memory, verbal fluency, and executive functions. Two-step hierarchical regression analysis revealed that higher PRS was significantly associated with lower scores in working memory tasks [Letter Number Span: Δ Allele polymorphisms may modify the effect of other AD risk factors. This potential modulation warrants further investigations, particularly in cognitively healthy adults.
Sections du résumé
Background
UNASSIGNED
Alzheimer's disease (AD) pathology is present many years before the onset of clinical symptoms. AD dementia cannot be treated. Timely and early detection of people at risk of developing AD is key for primary and secondary prevention. Moreover, understanding the underlying pathology that is present in the earliest stages of AD, and the genetic predisposition to that might contribute to the development of targeted disease-modifying treatments.
Objectives
UNASSIGNED
In this study, we aimed to explore whether genetic disposition to AD in asymptomatic individuals is associated with altered intrinsic functional connectivity as well as cognitive performance on neuropsychological tests.
Methods
UNASSIGNED
We examined 136 cognitively healthy adults (old group: mean age = 69.32, SD = 4.23; young group: mean age = 31.34, SD = 13.12). All participants had undergone resting-state functional magnetic resonance imagining (fMRI), DNA genotyping to ascertain polygenic risk scores (PRS), and neuropsychological testing for global cognition, working memory, verbal fluency, and executive functions.
Results
UNASSIGNED
Two-step hierarchical regression analysis revealed that higher PRS was significantly associated with lower scores in working memory tasks [Letter Number Span: Δ
Conclusion
UNASSIGNED
Allele polymorphisms may modify the effect of other AD risk factors. This potential modulation warrants further investigations, particularly in cognitively healthy adults.
Identifiants
pubmed: 35645768
doi: 10.3389/fnagi.2022.837284
pmc: PMC9131016
doi:
Types de publication
Journal Article
Langues
eng
Pagination
837284Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Ibnidris, Fußer, Kranz, Prvulovic, Reif, Pantel, Albanese, Karakaya and Matura.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurobiol Aging. 2016 May;41:150-158
pubmed: 27103528
Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):269-282
pubmed: 27781389
Neurobiol Aging. 2012 Apr;33(4):828.e19-30
pubmed: 21840627
PLoS Biol. 2008 Jul 1;6(7):e159
pubmed: 18597554
Transl Psychiatry. 2019 Jun 11;9(1):167
pubmed: 31186402
Neuroimage. 2001 May;13(5):903-19
pubmed: 11304086
Lancet Neurol. 2021 Jan;20(1):68-80
pubmed: 33340485
eNeuro. 2016 Jul 15;3(3):
pubmed: 27482534
Neuroimage. 2013 Feb 1;66:28-35
pubmed: 23128076
Alzheimers Dement. 2016 Apr;12(4):373-9
pubmed: 26588863
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
J Clin Exp Neuropsychol. 1988 Dec;10(6):739-53
pubmed: 3235648
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Brain. 2020 Apr 1;143(4):1233-1248
pubmed: 32252068
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Curr Neurol Neurosci Rep. 2014 Oct;14(10):491
pubmed: 25120223
Alzheimers Dement (N Y). 2021 May 18;7(1):e12177
pubmed: 34027027
Gigascience. 2019 Jul 1;8(7):
pubmed: 31307061
Acta Neuropsychiatr. 2021 Jun;33(3):134-140
pubmed: 33478614
Cereb Cortex. 2009 Jan;19(1):72-8
pubmed: 18403396
J Neurosci. 2005 Aug 24;25(34):7709-17
pubmed: 16120771
J Neurol Sci. 2003 Nov 15;215(1-2):71-4
pubmed: 14568131
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
J Alzheimers Dis. 2016 Mar 16;52(1):317-31
pubmed: 27003211
Front Digit Health. 2020 Aug 11;2:14
pubmed: 34713027
Eur J Neurosci. 2014 Oct;40(7):3128-35
pubmed: 24989884
Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan 1;1(1):14-23
pubmed: 26858991
Neuroimage. 2007 Oct 1;37(4):1091-6; discussion 1097-9
pubmed: 17368915
Nat Commun. 2017 Oct 31;8(1):1214
pubmed: 29089479
Psychopharmacol Bull. 1988;24(4):641-52
pubmed: 3249766
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Nature. 2016 Aug 31;537(7618):50-6
pubmed: 27582220
Behav Brain Res. 2009 Jan 30;197(1):103-8
pubmed: 18786570
Brain Struct Funct. 2015;220(3):1463-75
pubmed: 24578178
Mol Psychiatry. 2019 Mar;24(3):421-430
pubmed: 29487403
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18760-5
pubmed: 18003904
Neurology. 2016 Aug 2;87(5):481-8
pubmed: 27385740
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82
pubmed: 11209064
Neuron. 2019 Mar 6;101(5):820-838
pubmed: 30844401
Neurology. 2018 May 1;90(18):e1605-e1612
pubmed: 29592889
J Alzheimers Dis. 2018;64(3):801-813
pubmed: 29914027
Neuroimage. 2014 Apr 1;89:81-91
pubmed: 24296331
J Alzheimers Dis. 2015;45(3):781-95
pubmed: 25624419
Aging Clin Exp Res. 2011 Oct-Dec;23(5-6):487-90
pubmed: 22526081
Arch Gen Psychiatry. 1997 Feb;54(2):159-65
pubmed: 9040284
Neurobiol Aging. 2014 Oct;35(10):2422.e3-8
pubmed: 24863667
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Neuropsychol Rev. 2003 Jun;13(2):79-92
pubmed: 12887040
BMJ. 2021 Jul 5;374:n1682
pubmed: 34226181
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
Int Psychogeriatr. 1992 Fall;4(2):165-76
pubmed: 1477304
J Int Neuropsychol Soc. 2023 Feb;29(2):136-147
pubmed: 35184795
Alzheimers Dement. 2014 Jan;10(1):76-83
pubmed: 23375567
Nat Commun. 2021 Jul 23;12(1):4506
pubmed: 34301930
Br Med J. 1964 Jul 18;2(5402):177
pubmed: 14150898
Psychol Aging. 1989 Dec;4(4):500-3
pubmed: 2619956
Front Syst Neurosci. 2017 Apr 06;11:19
pubmed: 28428747
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Neuropsychology. 2011 Mar;25(2):237-48
pubmed: 21381828
Acta Neuropsychiatr. 2020 Aug;32(4):206-213
pubmed: 31801648
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42
pubmed: 15070770
Biomedicines. 2019 Dec 09;7(4):
pubmed: 31835422
Cereb Cortex. 2011 Oct;21(10):2399-407
pubmed: 21383234
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Curr Alzheimer Res. 2011 Jun;8(4):361-5
pubmed: 21222595
Neurobiol Aging. 2012 Sep;33(9):2018-28
pubmed: 21862179
N Engl J Med. 2000 Aug 17;343(7):450-6
pubmed: 10944562
Neuroimage. 2004 Feb;21(2):757-67
pubmed: 14980579
Neuron. 2009 Jul 30;63(2):178-88
pubmed: 19640477
Alzheimers Res Ther. 2018 Feb 07;10(1):15
pubmed: 29415768
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248